Pregledni rad
https://doi.org/10.20471/LO.2018.46.01.05
Taxanes in adjuvant breast cancer treatment
Ana Tečić Vuger
orcid.org/0000-0003-2203-161X
; Department of Radiotherapy and Medical Oncology , University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb
Mirjana Pavlović
; Department of Radiotherapy and Medical Oncology , University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb
Nikolina Lonjak
; Department of Radiotherapy and Medical Oncology , University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb
Milena Gnjidić
; Department of Oncology, Division of Medical Oncology, University Hospital Center Zagreb, Croatia
Ljubica Vazdar
; Department of Radiotherapy and Medical Oncology , University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb
Vesna Pavlica
; Hospital Pharmacy, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb
Robert Šeparović
; Department of Radiotherapy and Medical Oncology , University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb
Sažetak
Taxanes are irreplaceble drugs in treatment of many solid malignancies. In breast cancer they represent the backbone of adjuvant therapy and are important option in treatment of advanced and metastatic disease. Since their discovery in 1960’s they went through a long journey of clinical development and positioning in clinical practise of treatment of early breast cancer. Taxanes belong to the fourth group of cytotoxic drugs, which act as mytotic inhibitors, causing the death of the cell in metaphase. Clinical trials conducted in patients with breast cancer evaluated different combinations of other chemotherapeutics
with taxanes, different modes of administration, effectiveness of different chemotherapy regimens including taxanes in different subtypes and stages of the disease and effectiveness of individual taxanes in comparison with one another. Based on the results of those trials, today the relevant global oncology associations reccomend the use of taxanes in treatment of early breast cancer, pointing out their significant benefit in total reduction of breast cancer mortality and risk of disease reccurence by 20-30% comparing to anthracycline only protocols. The purpose of this literature review was to provide comprehensive information about development of taxanes and their position in routine everyday clinical practise.
Ključne riječi
taxanes; mytotic inhibitors; cytotoxic drugs; chemotherapy regimens; early breast cancer
Hrčak ID:
204712
URI
Datum izdavanja:
20.7.2018.
Posjeta: 1.949 *